Off Script: A Pharma Manufacturing Podcast
By Pharma Manufacturing
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Pharma Manufacturing
Category: Business News
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 9
Reviews: 0
Episodes: 115
Description
The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more!
| Episode | Date |
|---|---|
|
Modular Flow Chemistry and the Future of Continuous Manufacturing
|
Dec 09, 2025 |
|
The Economics Behind U.S. Generic Drug Manufacturing: Part Two
|
Nov 25, 2025 |
|
The Economics Behind U.S. Generic Drug Manufacturing: Part One
|
Nov 20, 2025 |
|
CGT Manufacturing Challenges and Opportunities
|
Nov 11, 2025 |
|
The State of CDMO Funding: 2025 in Review (Part Two)
|
Nov 04, 2025 |
|
The State of CDMO Funding: 2025 in Review (Part One)
|
Oct 28, 2025 |
|
Corporate compliance involves more than just cGMP and quality
|
Oct 17, 2025 |
|
Charting Pharma Manufacturing Trends: Part Two
|
Oct 14, 2025 |
|
Charting Pharma Manufacturing Trends: Part One
|
Oct 07, 2025 |
|
Editor’s (re)View: It matters if Big Pharma is fudging its US investment numbers
|
Sep 16, 2025 |
|
Can CDMOs keep up with the increasing demand for GLP-1 medications?
|
Sep 10, 2025 |
|
FDA’s program to speed up US manufacturing buildouts is short on detail
|
Aug 26, 2025 |
|
New Jersey remains hot life sciences hub despite macroeconomic, funding headwinds
|
Aug 19, 2025 |
|
Critical Timing: Hikma’s Billion-Dollar U.S. Investment
|
Jul 15, 2025 |
|
Editor’s (re)View: Is the biopharma industry’s glass half empty or half full?
|
Jul 01, 2025 |
|
Life sciences manufacturers overwhelmingly embrace smart tech: global survey
|
Jun 26, 2025 |
|
Flow state: The evolving shape of continuous manufacturing
|
Jun 23, 2025 |
|
[Solutions Spotlight] Hydrogenation: Bridging the gap between nitration and phosgenation
|
May 12, 2025 |
|
Editor’s (re)View: BMS, Merck, Roche see manufacturing flexibility as key to dealing with tariffs
|
Apr 30, 2025 |
|
Thermo Fisher opens cell therapy center, FDA cites Aurobindo site, Trump probes pharma imports ahead of tariffs [The good, the bad, the ugly]
|
Apr 21, 2025 |
|
Novartis to invest $23B in US sites, US urged to invest $15B in biotech counter to China, Trump warns of major pharma tariffs [The good, the bad, the ugly]
|
Apr 14, 2025 |
|
Cellares, Cabaletta validate automated CAR T production, FDA warns Aspen over sterility issues, rejects Hengrui, Elevar cancer combo again [The good, the bad, the ugly]
|
Mar 26, 2025 |
|
Axplora expands ADC capacity, Merck KGaA CDMO business slump, FDA issues a warning letter to Granules India [The good, the bad, the ugly]
|
Mar 17, 2025 |
|
Eli Lilly expands manufacturing to boost supply, FDA blocks imports from two Indian API makers, ICU Medical recalls potassium chloride injection bags over labeling error [The good, the bad, the ugly]
|
Feb 25, 2025 |
|
Novartis boosts Slovenia investment to $3.6B, Trump tariffs could unsettle biopharma FDI, FDA warns Global Calcium, blocks US imports [The good, the bad, the ugly]
|
Feb 18, 2025 |
|
FDA approves Opdivo subcutaneous version, Marinus Pharmaceuticals sells operations, Novo Nordisk pushes back against compounding pharmacies [The good, the bad, the ugly]
|
Jan 07, 2025 |
|
EU approves Novo-Catalent acquisition, CDMO National Resilience announces layoffs, FDA investigates blood cancer reports in gene therapy patients [The good, the bad, the ugly]
|
Dec 13, 2024 |
|
FDA approves Imkeldi oral solution, Alector axes workforce, Novartis announcnes layoffs [The good, the bad, the ugly]
|
Dec 09, 2024 |
|
FDA grants Regenxbio accelerated path for Duchenne, Neurogene reports death in Rett trial, Halozyme drops Evotec bid [The good, the bad, the ugly]
|
Nov 26, 2024 |
|
PTC secures FDA nod, Kronos Bio halts CDK9 development, Marinus slashes 45% of workforce amid setbacks [The good, the bad, the ugly]
|
Nov 21, 2024 |
|
Ascendis, Novo ink partnership, Court blocks Sun Pharma launch, FDA moves to delist phenylephrine [The good, the bad, the ugly]
|
Nov 14, 2024 |
|
MilliporeSigma expands ADC manufacturing, EU fines Teva, AZ exec under investigation in China [The good, the bad, the ugly]
|
Nov 06, 2024 |
|
[Extended Release] Antibiotic resistance crisis and the global efforts against superbugs
|
Oct 30, 2024 |
|
Nucleus RadioPharma expands production with new sites, FDA issues CRL to Camurus' hormone disorder drug, NHS rejects Eli Lilly's Alzheimer's drug over cost [The good, the bad, the ugly]
|
Oct 28, 2024 |
|
FDA approves AbbVie 24-hour Parkinson’s treatment, Sage Therapeutics axes workforce, FDA halts Novavax's COVID-flu vax trials [The good, the bad, the ugly]
|
Oct 21, 2024 |
|
Roche gets FDA nod for breast cancer combo, Kezar’s lupus drug trial on hold, Zealand Pharma’s hypoglycemia drug rejected over manufacturing [The good, the bad, the ugly]
|
Oct 14, 2024 |
|
Gilead inks deal with generics manufacturers to expand HIV drug access, J&J announces layoffs, Amgen sued for hiding $10.7B tax bill [The good, the bad, the ugly]
|
Oct 07, 2024 |
|
FDA approves BMS schizophrenia drug, bluebird bio announces layoffs, J&J talc subsidiary files for bankruptcy [The good, the bad, the ugly]
|
Sep 30, 2024 |
|
[Extended Release] Schizophrenia treatment barriers, KarXT, and the future of neuroscience
|
Sep 26, 2024 |
|
Novo Nordisk shares phase 2a obesity trial data, Achilles Therapeutics ends TIL-based therapy, Express Scripts sues FTC [The good, the bad, the ugly]
|
Sep 23, 2024 |
|
[Solutions Spotlight] Optimizing contamination control in pharma facilities
|
Sep 19, 2024 |
|
Roche wins FDA approval for subcutaneous cancer immunotherapy, Moderna to cut $1.1B in R&D expenses, Teva settles $80M opioid case with Baltimore [The good, the bad, the ugly]
|
Sep 16, 2024 |
|
Pfizer, Valneva share phase 2 Lyme vax data, IN8bio axes workforce, AstraZeneca employees detained in China [The good, the bad, the ugly]
|
Sep 09, 2024 |
|
FDA approves Illumina cancer biomarker test, BioMarin reveals more layoffs, FDA hits API maker Global Calcium with 483 [The good, the bad, the ugly]
|
Sep 03, 2024 |
|
Pharma’s new age of longevity
|
Aug 28, 2024 |
|
Emergent donates 50k doses of mpox vaccine to Africa, FDA rejects Regeneron blood cancer bispecific antibody, China indicts Astellas exec for espionage [The good, the bad, the ugly]
|
Aug 26, 2024 |
|
FDA approves Ascendis drug, Lykos PTSD treatment rejected, Novartis bid blocked [The good, the bad, the ugly]
|
Aug 19, 2024 |
|
Amneal's Parkinson's pill approved, Novo Nordisk withdraws Wegovy approval expansion bid, FDA delays BeiGene Tevimbra decision [The good, the bad, the ugly]
|
Aug 12, 2024 |
|
FDA approves Adaptimmune therapy, halts vTv diabetes program; Sanofi sues Sarepta over Duchenne patents [The good, the bad, the ugly]
|
Aug 05, 2024 |
|
FDA approves Sun Pharma hair loss drug, FDA issues warning letter to Brassica, EMA rejects Eisai-Biogen Alzheimer's drug [The good, the bad, the ugly]
|
Jul 29, 2024 |
|
Genentech's oral weight loss drug shows promise; FDA denies accelerated approval for Agenus' cancer drug; Orexo's opioid overdose drug rejected again [The good, the bad, the ugly]
|
Jul 22, 2024 |
|
Pfizer advances obesity pill, FDA rejects Novo insulin, FTC releases PBM report [The good, the bad, the ugly]
|
Jul 15, 2024 |
|
Lilly Alzheimer’s drug gets full approval, Rocket gene therapy rejected, Eisai, BMS end ADC partnership [The good, the bad, the ugly]
|
Jul 08, 2024 |
|
[Solutions Spotlight] Streamlining oral dose packaging design
|
Jul 03, 2024 |
|
Verona wins COPD nod, FDA rejects Merck-Daiichi ADC, Glenmark recalls potassium chloride capsules [The good, the bad, the ugly]
|
Jul 01, 2024 |
|
Gilead HIV shot delivers zero infections, Takeda epilepsy drug misses endpoints, Lilly goes after counterfeiters [The good, the bad, the ugly]
|
Jun 24, 2024 |
|
FDA backs Lilly Alzheimer’s drug; Pfizer Duchenne gene therapy fails; Talc plaintiffs seek J&J bankruptcy restraining order [The good, the bad, the ugly]
|
Jun 18, 2024 |
|
AZ's Tagrisso shines in phase 3 trial, BMS layoffs, FDA violations at Jiangsu Hengrui site [The good, the bad, the ugly]
|
Jun 10, 2024 |
|
J&J depression drug aces trial, Takeda plans layoffs, FDA delays review of Sanofi-Regeneron's Dupixent [The good, the bad, the ugly]
|
Jun 03, 2024 |
|
Mining pharma's reshoring rush
|
May 29, 2024 |
|
FDA approves biosim to Regeneron Eylea, Evotec exits gene therapy, J&J reports deaths in radioligand trial [The good, the bad, the ugly]
|
May 28, 2024 |
|
FDA approves Amgen's T-cell engager for lung cancer, BioMarin announces layoffs, FDA delays Ascendis drug review [The good, the bad, the ugly]
|
May 20, 2024 |
|
Vertex submits NDA for CF drug, MacroGenics reports ADC prostate cancer trial patient deaths, FTC extends review of Novo-Catalent deal [The good, the bad, the ugly]
|
May 13, 2024 |
|
Neurocrine wins FDA nod for 'sprinkle' Ingrezza, Moderna-Metagenomi deal ends, Emergent's layoffs [The good, the bad, the ugly]
|
May 06, 2024 |
|
Novartis wins rare cancer pediatric indication, BMS layoffs, McKinsey under fire [The good, the bad, the ugly]
|
Apr 29, 2024 |
|
GSK antibiotic hits phase 3 goals, Genentech-Adaptimmune collab ends, Par Pharma recall [The good, the bad, the ugly]
|
Apr 22, 2024 |
|
BMS schizophrenia drug shines, Novartis axes jobs, Lilly compounding suit dismissed [The good, the bad, the ugly]
|
Apr 22, 2024 |
|
2024 election's impact on manufacturing
|
Apr 12, 2024 |
|
Basilea grabs FDA nod, Verve halts gene editing trial, Amylyx pulls ALS drug [The good, the bad, the ugly]
|
Apr 08, 2024 |
|
[The good, the bad, the ugly] Editor's Review week of March 25
|
Apr 01, 2024 |
|
[The good, the bad, the ugly] Editor's Review week of March 18
|
Mar 25, 2024 |
|
[The good, the bad, the ugly] Editor's Review week of March 11
|
Mar 18, 2024 |
|
[The good, the bad, the ugly] Editor's Review week of March 4
|
Mar 11, 2024 |
|
[The good, the bad, the ugly] Editor's Review week of February 29
|
Mar 05, 2024 |
|
[The good, the bad, the ugly] Editor's Review week of February 23
|
Mar 01, 2024 |
|
Raising a modern CDMO
|
Feb 27, 2024 |
|
[Solutions Spotlight] Meeting today’s container closure integrity requirements
|
Sep 21, 2023 |
|
[Solutions Spotlight] Ensuring quality during a syringe surge
|
Aug 09, 2023 |
|
[Solutions Spotlight] Overcoming drug formulation challenges
|
Jan 19, 2023 |
|
[Solutions Spotlight] Bringing pharma’s asset management into the digital age
|
Oct 26, 2022 |
|
[Solutions Spotlight] How to overcome challenges in ophthalmic formulations
|
Oct 17, 2022 |
|
[Solutions Spotlight] How digitalization can provide a competitive advantage
|
Jun 17, 2022 |
|
[Solutions Spotlight] Stop the stall: The time is now for predictive maintenance in pharma
|
May 24, 2022 |
|
[Solutions Spotlight] A groundbreaking approach to BET testing
|
Nov 23, 2021 |
|
[Solutions spotlight] A better way to measure critical attributes in bioreactors
|
Oct 26, 2021 |
|
[Solutions Spotlight] Special delivery: Lipid nanoparticles usher in new treatments
|
Oct 04, 2021 |
|
[Solutions Spotlight] Harnessing AI to improve workplace ergonomics
|
Aug 09, 2021 |
|
Is it time to call the dogs off drug testing?
|
Jun 16, 2021 |
|
Drugs down the drain
|
May 24, 2021 |
|
[Solutions Spotlight] Elevating quality inspection with AI
|
Apr 30, 2021 |
|
Inside the FDA’s fateful Alzheimer’s decision
|
Mar 19, 2021 |
|
Growing the biologic drug supply
|
Feb 26, 2021 |
|
Will the FDA keep moving at this breakneck pace?
|
Feb 01, 2021 |
|
Pharma's wild ride through 2020
|
Dec 30, 2020 |
|
Saving the shrinking pipeline for antibiotics
|
Nov 16, 2020 |
|
Reaching undecided vaxxers: Can pharma simultaneously advance vaccines and public trust
|
Nov 02, 2020 |
|
[Solutions Spotlight] Pharma’s drive towards more sustainable packaging
|
Oct 29, 2020 |
|
Pharma's next big hurdle — distributing vaccines
|
Oct 19, 2020 |
|
The United States of Generics
|
Oct 05, 2020 |